List of Studies ( Metabolite:1-DeoxyCer 18:0;O/18:0)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Units(range) |
|---|---|---|---|---|---|---|---|
| ST000916 | AN001495 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Plasma | Blood | Human | Fatty liver disease | LIPID MAPS | nM |
| ST000917 | AN001501 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 3:Urine | Urine | Human | Fatty liver disease | LIPID MAPS | nM |
| ST002340 | AN003823 | Serine supplementation and hepatic and skin sphingolipid diversity | Liver | Mouse | Salk Institute for Biological Studies | normalized ion count/mg protein | |
| ST002340 | AN003823 | Serine supplementation and hepatic and skin sphingolipid diversity | Skin | Mouse | Salk Institute for Biological Studies | normalized ion count/mg protein | |
| ST002343 | AN003827 | The impact of myriocin and dietary serine restriction on paw skin sphingolipid diversity | Skin | Mouse | Salk Institute for Biological Studies | normalized ion count/mg protein | |
| ST002344 | AN003828 | The impact of dietary serine/glycine restriction and myriocin treatment on hepatic sphingolipid diversity during prolonged high fat diet feeding. | Liver | Mouse | Salk Institute for Biological Studies | normalized ion count/mg protein | |
| ST001063 | AN001740 | Lipidomics analysis for aged mice organs | Adipose tissue | Mouse | Takeda Pharmaceutical Company Limited | Peak area | |
| ST001063 | AN001740 | Lipidomics analysis for aged mice organs | Brain | Mouse | Takeda Pharmaceutical Company Limited | Peak area | |
| ST001063 | AN001740 | Lipidomics analysis for aged mice organs | Liver | Mouse | Takeda Pharmaceutical Company Limited | Peak area | |
| ST001063 | AN001740 | Lipidomics analysis for aged mice organs | Muscle | Mouse | Takeda Pharmaceutical Company Limited | Peak area | |
| ST001065 | AN001743 | Lipidomics analysis for aged mice brain cortex (part-II) | Adipose tissue | Mouse | Takeda Pharmaceutical Company Limited | Peak area | |
| ST001065 | AN001743 | Lipidomics analysis for aged mice brain cortex (part-II) | Brain | Mouse | Takeda Pharmaceutical Company Limited | Peak area | |
| ST001065 | AN001743 | Lipidomics analysis for aged mice brain cortex (part-II) | Liver | Mouse | Takeda Pharmaceutical Company Limited | Peak area | |
| ST001065 | AN001743 | Lipidomics analysis for aged mice brain cortex (part-II) | Muscle | Mouse | Takeda Pharmaceutical Company Limited | Peak area | |
| ST001067 | AN001747 | Lipidomics analysis for aged mice femoral muscle (part - IV) | Adipose tissue | Mouse | Takeda Pharmaceutical Company Limited | Peak area | |
| ST001067 | AN001747 | Lipidomics analysis for aged mice femoral muscle (part - IV) | Brain | Mouse | Takeda Pharmaceutical Company Limited | Peak area | |
| ST001067 | AN001747 | Lipidomics analysis for aged mice femoral muscle (part - IV) | Liver | Mouse | Takeda Pharmaceutical Company Limited | Peak area | |
| ST001067 | AN001747 | Lipidomics analysis for aged mice femoral muscle (part - IV) | Muscle | Mouse | Takeda Pharmaceutical Company Limited | Peak area | |
| ST002284 | AN003732 | Genetically defined human GBM organoids reveal principles of GBM development and actionable targets | Cultured cells | Human | Cancer | DKFZ | peak intensity |
| ST000915 | AN001489 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Liver | Liver | Human | Fatty liver disease | LIPID MAPS | pmol/mg |
